From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

CT023 - Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naïve/memory T cells for relapsed or refractory non-Hodgkin lymphoma

Last Updated: Friday, May 19, 2023

An investigational CD19/20-directed CAR T-cell therapy had a 91% overall response rate among adults with advanced non-Hodgkin lymphoma. The median overall survival has not yet been reached, with some remissions lasting more than 3 years post-infusion. 

AACR Meeting Abstract
Advertisement
News & Literature Highlights
Advertisement
Advertisement